Check-Cap (STU:7CC) Other Stockholders Equity: €-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7CC Check-Cap Ltd STU:7CC
37 GF Score
Price €0.98
! 2 Warning Signs
View Full Analysis

What is Check-Cap Other Stockholders Equity?

Check-Cap STU:7CC -5.34% 37 Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus rates STU:7CC with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Check-Cap's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €-0.00 Mil.

Check-Cap's quarterly Other Stockholders Equity increased from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€0.00 Mil) but then declined from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Check-Cap's annual Other Stockholders Equity declined from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Check-Cap Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Check-Cap's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Check-Cap Other Stockholders Equity Chart

Check-Cap Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00

Check-Cap Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.00 0.00 0.00 -0.00
STU:7CC
37GF Score
Check-Cap Ltd STU:7CC
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Check-Cap Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Check-Cap (STU:7CC) has a Other Stockholders Equity of €-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Check-Cap and its competitors.
Is Check-Cap's Other Stockholders Equity too high?
Check-Cap's current Other Stockholders Equity is €-0.00 Mil. Overall, Check-Cap has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Check-Cap's Other Stockholders Equity compare to ADVB and XWEL?
Check-Cap's Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Diagnostics & Research company?
A good Other Stockholders Equity depends on the Medical Diagnostics & Research industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Check-Cap and its competitors. Check-Cap's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Check-Cap stock overvalued right now?
Check-Cap (STU:7CC) has a current Other Stockholders Equity of €-0.00 Mil. The current Other Stockholders Equity is €-0.00 Mil. Check-Cap's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Check-Cap (STU:7CC), the current Other Stockholders Equity is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Check-Cap Business Description

Other Exchanges MBAI:USA
Address 29 Abba Hushi Avenue, P.O. Box 1271, Mount Carmel, Isfiya, ISR, 3009000
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.
37GF Score

Get the complete analysis for STU:7CC

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.98
Price